Payment overview · 2025
General Payments
$3,306.42
163 reported records · 24 companies
Healthcare provider profile · identity verified
Matthew Michael Ryan, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · OKLAHOMA CITY, OK · NPI 1003951500
Verified facts
What the public records show
CMS Open Payments records show Matthew Michael Ryan, MD received $3,306.42 in general payments during 2025 across 163 reported records.
ABBVIE INC. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Epidiolex, Ingrezza, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rytary by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Epidiolex by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ingrezza by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Xcopri by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,094.87 | 33.1% | 47 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $302.49 | 9.2% | 19 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $266.76 | 8.1% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $250.90 | 7.6% | 17 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$219.70 | 6.6% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $194.44 | 5.9% | 9 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $139.60 | 4.2% | 8 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $129.56 | 3.9% | 5 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $105.67 | 3.2% | 5 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $96.29 | 2.9% | 4 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $94.03 | 2.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $68.47 | 2.1% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.61 | 1.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.54 | 1.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.47 | 1.3% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $33.12 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.33 | 0.9% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $26.10 | 0.8% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $20.34 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.62 | 0.6% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $19.25 | 0.6% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.66 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $17.61 | 0.5% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.99 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,306.42 | 163 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $869.60 | 35 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $554.91 | 19 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $419.07 | 20 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $302.49 | 19 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $266.76 | 19 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $250.90 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $250.90 | 17 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $154.32 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $139.60 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $129.56 | 5 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $105.67 | 5 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $96.29 | 4 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $94.03 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $68.47 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $56.61 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $40.12 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $31.33 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $9.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
100 | 16 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
88 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 815 | 259 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 454 | 130 |
| Levetiracetam | Levetiracetam | 409 | 129 |
| Gabapentin | Gabapentin | 359 | 93 |
| Donepezil Hcl | Donepezil Hcl | 239 | 84 |
| Lacosamide | Lacosamide | 232 | 36 |
| Primidone | Primidone | 207 | 68 |
| Topiramate | Topiramate | 207 | 56 |
| Pregabalin | Pregabalin | 203 | 42 |
| Risperidone | Risperidone | 198 | 70 |
| Clonazepam | Clonazepam | 155 | 24 |
| Carbamazepine | Carbamazepine | 123 | 44 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 115 | 35 |
| Diazepam | Diazepam | 112 | 34 |
| Divalproex Sodium | Divalproex Sodium | 102 | 29 |
| Rytary | Carbidopa/Levodopa | 100 | 16 |
| Oxcarbazepine | Oxcarbazepine | 99 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 33 |
| Propranolol Hcl | Propranolol Hcl | 98 | 37 |
| Lamotrigine | Lamotrigine | 92 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 89 | 14 |
| Xcopri | Cenobamate | 88 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 86 | 30 |
| Rivastigmine | Rivastigmine Tartrate | 83 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 21 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 77 | 21 |
| Atorvastatin Calcium | Atorvastatin Calcium | 70 | 24 |
| Clobazam | Clobazam | 64 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 21 |
| Zonisamide | Zonisamide | 55 | suppressed |
| Rivastigmine | Rivastigmine | 54 | 15 |
| Baclofen | Baclofen | 49 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 17 |
| Nurtec Odt | Rimegepant Sulfate | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | 11 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | 12 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 36 | 16 |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | 13 |
| Eliquis | Apixaban | 34 | 13 |
| Ingrezza | Valbenazine Tosylate | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | 13 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | suppressed |
| Modafinil | Modafinil | 29 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 27 | suppressed |
| Prednisone | Prednisone | 27 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 22 | suppressed |
| Levetiracetam Er | Levetiracetam | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 18 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Glatopa | Glatiramer Acetate | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Lisinopril | Lisinopril | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,306.42 · 163 records | ABBVIE INC. | AJOVY, AUSTEDO XR, BOTOX, BRIUMVI, CREXONT, EPIDIOLEX, INBRIJA, INFINITY, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, QULIPTA, SKYCLARYS, TRUDHESA, UBRELVY, UPLIZNA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND, ZEPOSIA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Epidiolex play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error